Hap Trading, LLC Savara Inc Call Options Transaction History

Hap Trading, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$1.36 - $1.88 $17,952 - $24,816	-13,200 Reduced 47.48%	14,600 $0
Q2 2022 Aug 12, 2022	SELL	$1.1 - $1.58 $9,790 - $14,062	-8,900 Reduced 24.25%	27,800 $2,000
Q1 2022 May 12, 2022	BUY	$1.05 - $1.36 $12,285 - $15,912	11,700 Added 46.8%	36,700 $1,000
Q4 2021 Feb 14, 2022	BUY	$1.04 - $1.34 $26,000 - $33,500	25,000 New	25,000 $2,000
Q3 2021 Nov 10, 2021	SELL	$1.18 - $1.64 $13,334 - $18,532	-11,300 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$1.51 - $2.29 $28,992 - $43,968	-19,200 Reduced 62.95%	11,300 $1,000
Q1 2021 May 14, 2021	BUY	$1.17 - $2.33 $35,685 - $71,065	30,500 New	30,500 $10,000
Q1 2020 May 08, 2020	SELL	$1.91 - $4.08 $25,594 - $54,672	-13,400 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$0.71 - $4.91 $9,514 - $65,794	13,400 New	13,400 $13,000

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $383M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.